Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nano-TriNKE
- Development stage
- Preclinical
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
nano-TriNKE is a nanoparticle-based immunotherapy platform designed to target EGFR-overexpressing tumors while recruiting and activating natural killer (NK) cells. The platform is constructed using biocompatible PEG-PLGA nanoparticles functionalized with three distinct antibodies: cetuximab (targeting EGFR), anti-CD16, and anti-4-1BB. This trispecific configuration enables the simultaneous engagement of tumor cells and the activation of NK cells through both the CD16 and 4-1BB costimulatory pathways. Furthermore, the nano-TriNKE platform can encapsulate cytotoxic agents such as epirubicin, allowing for a combined chemo-immunotherapeutic approach. Developed as a research-stage biologic, it was first detailed in a 2020 publication in Science Advances.
- Other names
- epidermal growth factor receptor-targeting trispecific natural killer cell engagersEGFR-targeting trispecific NK cell engagerEGFR-nano-TriNKE
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)TNFRSF (TNF receptor superfamily)
Beyond the preview
Go deeper on nano-TriNKE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nano-TriNKE.